205 related articles for article (PubMed ID: 32728614)
1. Boosting Replication and Penetration of Oncolytic Adenovirus by Paclitaxel Eradicate Peritoneal Metastasis of Gastric Cancer.
Ishikawa W; Kikuchi S; Ogawa T; Tabuchi M; Tazawa H; Kuroda S; Noma K; Nishizaki M; Kagawa S; Urata Y; Fujiwara T
Mol Ther Oncolytics; 2020 Sep; 18():262-271. PubMed ID: 32728614
[TBL] [Abstract][Full Text] [Related]
2. Modulation of
Ogawa T; Kikuchi S; Tabuchi M; Mitsui E; Une Y; Tazawa H; Kuroda S; Noma K; Ohara T; Kagawa S; Urata Y; Fujiwara T
Mol Ther Oncolytics; 2022 Jun; 25():249-261. PubMed ID: 35615263
[TBL] [Abstract][Full Text] [Related]
3. Intraperitoneal Administration of p53-armed Oncolytic Adenovirus Inhibits Peritoneal Metastasis of Diffuse-type Gastric Cancer Cells.
Hori N; Tazawa H; Li Y; Okura T; Kikuchi S; Kuroda S; Ohara T; Noma K; Nishizaki M; Urata Y; Kagawa S; Fujiwara T
Anticancer Res; 2023 Nov; 43(11):4809-4821. PubMed ID: 37909979
[TBL] [Abstract][Full Text] [Related]
4. Salvage gastrectomy after intravenous and intraperitoneal paclitaxel (PTX) administration with oral S-1 for peritoneal dissemination of advanced gastric cancer with malignant ascites.
Kitayama J; Ishigami H; Yamaguchi H; Yamashita H; Emoto S; Kaisaki S; Watanabe T
Ann Surg Oncol; 2014 Feb; 21(2):539-46. PubMed ID: 23975319
[TBL] [Abstract][Full Text] [Related]
5. Comparative study of the antitumor activity of Nab-paclitaxel and intraperitoneal solvent-based paclitaxel regarding peritoneal metastasis in gastric cancer.
Kinoshita J; Fushida S; Tsukada T; Oyama K; Watanabe T; Shoji M; Okamoto K; Nakanuma S; Sakai S; Makino I; Furukawa H; Hayashi H; Nakamura K; Inokuchi M; Nakagawara H; Miyashita T; Tajima H; Takamura H; Ninomiya I; Fujimura T; Masakazu Y; Hirakawa K; Ohta T
Oncol Rep; 2014 Jul; 32(1):89-96. PubMed ID: 24859429
[TBL] [Abstract][Full Text] [Related]
6. Intraperitoneal administration of paclitaxel solubilized with poly(2-methacryloxyethyl phosphorylcholine-co n-butyl methacrylate) for peritoneal dissemination of gastric cancer.
Soma D; Kitayama J; Konno T; Ishihara K; Yamada J; Kamei T; Ishigami H; Kaisaki S; Nagawa H
Cancer Sci; 2009 Oct; 100(10):1979-85. PubMed ID: 19604244
[TBL] [Abstract][Full Text] [Related]
7. Synergistic antitumor effect mediated by a paclitaxel-conjugated polymeric micelle-coated oncolytic adenovirus.
Kasala D; Lee SH; Hong JW; Choi JW; Nam K; Chung YH; Kim SW; Yun CO
Biomaterials; 2017 Nov; 145():207-222. PubMed ID: 28869866
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of CDH11 Promotes Metastasis and Resistance to Paclitaxel in Gastric Cancer Cells.
Yang Z; Yan C; Yu Z; He C; Li J; Li C; Yan M; Liu B; Wu Y; Zhu Z
J Cancer; 2021; 12(1):65-75. PubMed ID: 33391403
[No Abstract] [Full Text] [Related]
9. Therapeutic Cell-Cycle-Decoy Efficacy of a Telomerase-Dependent Adenovirus in an Orthotopic Model of Chemotherapy-Resistant Human Stomach Carcinomatosis Peritonitis Visualized With FUCCI Imaging.
Yano S; Takehara K; Tazawa H; Kishimoto H; Urata Y; Kagawa S; Fujiwara T; Hoffman RM
J Cell Biochem; 2017 Nov; 118(11):3635-3642. PubMed ID: 27171483
[TBL] [Abstract][Full Text] [Related]
10. Bone and Soft-Tissue Sarcoma: A New Target for Telomerase-Specific Oncolytic Virotherapy.
Tazawa H; Hasei J; Yano S; Kagawa S; Ozaki T; Fujiwara T
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32085583
[TBL] [Abstract][Full Text] [Related]
11. A phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S-1 for treatment of gastric cancer with macroscopic peritoneal metastasis.
Yamaguchi H; Kitayama J; Ishigami H; Emoto S; Yamashita H; Watanabe T
Cancer; 2013 Sep; 119(18):3354-8. PubMed ID: 23798046
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells.
Watanabe T; Hioki M; Fujiwara T; Nishizaki M; Kagawa S; Taki M; Kishimoto H; Endo Y; Urata Y; Tanaka N; Fujiwara T
Exp Cell Res; 2006 Feb; 312(3):256-65. PubMed ID: 16356494
[TBL] [Abstract][Full Text] [Related]
13. Functional remodeling of intraperitoneal macrophages by oncolytic adenovirus restores anti-tumor immunity for peritoneal metastasis of gastric cancer.
Tabuchi M; Kikuchi S; Tazawa H; Okura T; Ogawa T; Mitsui E; Une Y; Kuroda S; Sato H; Noma K; Kagawa S; Ohara T; Ohtsuka J; Ohki R; Urata Y; Fujiwara T
Mol Ther Oncol; 2024 Jun; 32(2):200806. PubMed ID: 38745748
[TBL] [Abstract][Full Text] [Related]
14. Autophagy-inducing agents augment the antitumor effect of telerase-selve oncolytic adenovirus OBP-405 on glioblastoma cells.
Yokoyama T; Iwado E; Kondo Y; Aoki H; Hayashi Y; Georgescu MM; Sawaya R; Hess KR; Mills GB; Kawamura H; Hashimoto Y; Urata Y; Fujiwara T; Kondo S
Gene Ther; 2008 Sep; 15(17):1233-9. PubMed ID: 18580968
[TBL] [Abstract][Full Text] [Related]
15. An oncolytic adenovirus expressing interleukin-24 enhances antitumor activities in combination with paclitaxel in breast cancer cells.
Fang L; Cheng Q; Bai J; Qi YD; Liu JJ; Li LT; Zheng JN
Mol Med Rep; 2013 Nov; 8(5):1416-24. PubMed ID: 24042845
[TBL] [Abstract][Full Text] [Related]
16. Surgery after intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis or positive peritoneal cytology findings.
Ishigami H; Yamaguchi H; Yamashita H; Asakage M; Kitayama J
Gastric Cancer; 2017 Mar; 20(Suppl 1):128-134. PubMed ID: 28028665
[TBL] [Abstract][Full Text] [Related]
17. Intraperitoneal administration of a small interfering RNA targeting nuclear factor-kappa B with paclitaxel successfully prolongs the survival of xenograft model mice with peritoneal metastasis of gastric cancer.
Inoue M; Matsumoto S; Saito H; Tsujitani S; Ikeguchi M
Int J Cancer; 2008 Dec; 123(11):2696-701. PubMed ID: 18798274
[TBL] [Abstract][Full Text] [Related]
18. [Clinical significance and practice points of conversion therapy for gastric cancer with peritoneal metastasis].
Zhu Z
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Oct; 20(10):1094-1098. PubMed ID: 29130218
[TBL] [Abstract][Full Text] [Related]
19. Elevated alpha1-acid glycoprotein in gastric cancer patients inhibits the anticancer effects of paclitaxel, effects restored by co-administration of erythromycin.
Ohbatake Y; Fushida S; Tsukada T; Kinoshita J; Oyama K; Hayashi H; Miyashita T; Tajima H; Takamura H; Ninomiya I; Yashiro M; Hirakawa K; Ohta T
Clin Exp Med; 2016 Nov; 16(4):585-592. PubMed ID: 26359244
[TBL] [Abstract][Full Text] [Related]
20. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
